Thursday, 10 August 2017

Flow Chemistry & Microreactors: A Substitute for Traditional API Batch Manufacturing

Active pharmaceutical ingredients (APIs) are defined as the chemicals utilized to create pharmaceutical drugs. The active ingredients (AIs) are the biologically active substances within the drug and are the particular components accountable for the preferred effect they have on an individual having it. The Active Pharmaceutical Ingredients (API) market is said to reach USD 239.8 billion by 2025 with a healthy CAGR of over 6 % during the forecast period (from 2014 to 2025). The increasing occurrence levels of various diseases such as cancer, neurological diseases, cardiovascular diseases, and so on are some the major factors expected to drive the growth of the global industry in the near future.

New Technologies:

The continuous-flow technology includes the constant introduction of a stream of various chemical reactants into microreactor or a flow to give in a wanted reaction product on a constant basis. This technology can provide various potential benefits as compared to the traditional batch production of pharmaceuticals, for example, superior control & optimization of the process, an improved environmental profile & safety for a given process, and a lowered manufacturing footprint as compared to the batch reactor systems.

New Facility by Lonza Group:

The growing interest in microreactor technology for fine-chemical manufacturing, Lonza Group has invested in a new facility that will offer the creation of APIs and multiton intermediates based on the continuous-flow technology. At present, the company is operating the assets that can manufacture some kilograms to some tons of small-molecule APIs with the help of microreactors. This new facility can offer an incorporated solution where all the common unit functions in flow can be managed in a flexible manner with microreactors—FlowPlate by Lonza.

Market Insights:

The global active pharmaceutical ingredients (APIs) market is expected to witness lucrative growth over the next few years. The growing advancements in the recombinant molecular technologies and extensive capitalization for the development of new drugs are also likely to propel the market growth. The key players in the Active Pharmaceutical Ingredients (API) market are Teva Pharmaceutical Industries Ltd.; AbbVie, Inc.; and Cipla, Inc. New collaborations, acquisitions, regional expansions, and molecule launches are some of the key strategies followed by all these market players in order to maintain a stable position and market share.

In-Depth research report on active pharmaceutical ingredients (APIs) market:

No comments:

Post a Comment

Ophthalmic Ultrasound Devices Market - Global Forecasts to 2026 by Grand View Research, Inc.

19-Mar-2020: The global ophthalmic ultrasound devices market size is expected to reach USD 728.7 million by 2026, according to a new repo...